- Company
- GSK Duodart can be prescribed at general hospitals
- by Eo, Yun-Ho Nov 22, 2022 06:04am
- Duodart, a prostate hypertrophy compound, has settled in general hospitals. According to related industries, GSK Korea's Duodart recently passed DC of Big 5 General Hospitals such as Samsung Medical Center, Seoul National University Hospital, Asan Medical Center, and Sinchon Severance Hospital. This drug has been applied to insurance benefits
- Policy
- Phase 3 of Fitusiran, an all-around tx for hemophilia
- by Lee, Hye-Kyung Nov 22, 2022 06:04am
- Phase 3 clinical trials of Fitusiran, a treatment candidate substance that is effective for both hemophilia A and B, are also being conducted in Korea. The Ministry of Food and Drug Safety approved a phase 3 clinical trial of Sanofi-Aventis Korea on the 18th. This clinical trial is a phase 3, single group, multi-organ, multinational clinical
- Policy
- Gov't declines preferential pricing for innovative drugs
- by Lee, Jeong-Hwan Nov 21, 2022 05:56am
- Complaints are rising in various areas of the pharmaceutical industry with the Ministry of Health and Welfare maintaining its position that preferential pricing for new drugs manufactured by Korea Innovative Pharmaceutical Companies cannot be introduced in practicality due to issues including trade conflict, NHI finances, etc. The indust
- Company
- Evrysdi can be prescribed with non-reimbursement
- by Eo, Yun-Ho Nov 21, 2022 05:56am
- Evrysdi, an eating spinal muscular atrophy treatment, can be prescribed at hospitals and is still non-reimbursement. According to related industries, Roche Korea's Spinal Muscular Atrophy treatment passed through D.C. at medical institutions such as Severance Hospital, Seoul National University Hospital, Yangsan Pusan National University Hosp
- Policy
- Label for rosuvastatin to change following ticagrelor
- by Lee, Hye-Kyung Nov 21, 2022 05:56am
- The drug-drug interaction label for rosuvastatin drugs that are used to treat hyperlipidemia including AstraZeneca’s ‘Crestor’ will be changed. The drugs that affect rosuvastatin are ticagrelor drugs including AstraZeneca’s antiplatelet drug ‘Brilinta.’ The labeling change for ticagrelor has been preannounced by the Ministry of Foo
- Company
- Dong-AST ended the clinical trial of Stelara biosimilar
- by Chon, Seung-Hyun Nov 21, 2022 05:56am
- Dong-AST announced on the 17th that the global phase 3 clinical trial of Stella biosimilar DMB-3115 has ended. Phase 3 of global clinical trials of DMB-3115 was conducted for 52 weeks in a total of 605 patients in 9 countries, including Poland, Estonia, and Latvia, starting in the United States in 2021. Phase 3 of this global clinical trial w
- Policy
- Public policy fee for severely ill children is implemented
- by Kim, Jung-Ju Nov 21, 2022 05:56am
- The government will push for a pilot project for a new payment system for the sustainability of treatment for severely ill children and adolescents. The Ministry of Health and Welfare (Minister Cho Kyu-hong) announced that it will recruit participating institutions for about four weeks from today (17th) to December 15th, which will take effec
- InterView
- “Korea is fully capable of developing new microbiome drugs"
- by Nho, Byung Chul Nov 18, 2022 06:04am
- “The development of metagenomics technology that extracts DNA directly from samples without culturing in 1998 enabled the field of human microbiome research to make a giant leap forward. The success and failure of innovative new microbiome-based therapeutics depend on identifying, standardizing, and materializing the keystone species in the
- Company
- KPBMA visits Boston...expands exchanges with MIT, etc.
- by Chon, Seung-Hyun Nov 18, 2022 06:04am
- On the 17th, Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) announced that its delegation had visited Boston, US to network with local companies and institutions. Hee-Mok Won, Director of KPBMA, Sung-Tae Yoon, Chairman of KPBMA, and other representatives of Korea’s pharmaceutical and bio business attended the exec
- Policy
- The budget for Paxlovid's SE relief will be prepared
- by Lee, Jeong-Hwan Nov 18, 2022 06:04am
- The Welfare Committee approved a budget of 1.7 billion won. Payment can be made next year if the plenary session is passed. The budget for relieving abnormal cases and side effects of drugs being administered in Korea through the EUA system, which is not approved based on the current Pharmaceutical Act, is smoothly being secured. This is beca
